Company intelligence / Profile preview
Yunnan Sunway Pharmaceutical
Kunming, Yunnan, Chinasainuozhiyao.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
SINOWAY markets several established drugs including amlodipine mesylate (hypertension), Kangfuxin (gastrointestinal and wound indications), and Ganlong Capsule (chronic hepatitis), as well as Periplaneta americana extract-based products. The company has developed a novel immunotoxin (SN-001) in early preclinical development.
- Therapeutic areas
- DermatologyGastroenterologyRare DiseasesInfectious DiseasesCardiovascularHematology
- Modalities
- Small moleculeBiologicMonoclonal antibodyImmunotoxinNatural product
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Shanghai Jiaotong University (immunotoxin development)Jecho Laboratories, Inc. (Periplaneta americana research)Over 20 pharmacy chains in China for distribution
Beyond the preview
Go deeper on Yunnan Sunway Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yunnan Sunway Pharmaceutical.